Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?
Abstract Introduction Atorvastatin is regarded as the most frequently prescribed statin worldwide for dyslipidemia. However, clinical response and risk of adverse effects to statin therapy are associated with genetic variations. Numerous research linked statins pharmacokinetics (PK) variations to ge...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-09-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-023-01038-1 |
| _version_ | 1797577341446127616 |
|---|---|
| author | Mohammed G. Maslub Mahasen A. Radwan Nur Aizati Athirah Daud Abubakar Sha’aban |
| author_facet | Mohammed G. Maslub Mahasen A. Radwan Nur Aizati Athirah Daud Abubakar Sha’aban |
| author_sort | Mohammed G. Maslub |
| collection | DOAJ |
| description | Abstract Introduction Atorvastatin is regarded as the most frequently prescribed statin worldwide for dyslipidemia. However, clinical response and risk of adverse effects to statin therapy are associated with genetic variations. Numerous research linked statins pharmacokinetics (PK) variations to genetic polymorphisms in cytochromes P450 (CYPs) metabolic enzymes. Objective This article reviews the association between CYP3A4/5 genetic variations and response to atorvastatin therapy globally, which includes atorvastatin PK, and the risk for adverse reactions, with a hint to the Egyptians. Methods Up to March 30, 2022, electronic medical databases like PubMed, Web of Science, MEDLINE, and Egyptian Knowledge Bank (EKB) were searched. All articles that highlighted the relationship between CYP3A4/5 genetic polymorphisms and atorvastatin efficacy/safety profile were included in this review. Results Initially, 492 articles were retrieved after an exhaustive search. There were 24 articles included according to the inclusion criteria. Findings of association studies of CYP3A4/5 genetic polymorphisms with response to atorvastatin varied among different ethnicities. CYP3A4*1B was associated with better therapeutic outcomes after atorvastatin therapy in Chileans and vice versa in Americans. Caucasians with myalgia while using atorvastatin were at significant risk of suffering severe muscle damage if they were carriers of CYP3A5*3/*3. As far as we can report for the Egyptian population, the impact of CYP3A4/5 genetic variations on the response to atorvastatin therapy was understudied. Conclusion More pharmacogenetic studies amongst diverse populations worldwide, like the Egyptian population, are necessary to detect further atorvastatin-gene interactions. Graphical Abstract |
| first_indexed | 2024-03-10T22:06:53Z |
| format | Article |
| id | doaj.art-eeb887001c3d471ba3ee78126c068e1b |
| institution | Directory Open Access Journal |
| issn | 2047-783X |
| language | English |
| last_indexed | 2024-03-10T22:06:53Z |
| publishDate | 2023-09-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj.art-eeb887001c3d471ba3ee78126c068e1b2023-11-19T12:46:38ZengBMCEuropean Journal of Medical Research2047-783X2023-09-0128111110.1186/s40001-023-01038-1Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?Mohammed G. Maslub0Mahasen A. Radwan1Nur Aizati Athirah Daud2Abubakar Sha’aban3Pharmacy Practice/Clinical Pharmacy Department, Faculty of Pharmacy, Egyptian Russian UniversityPharmacy Practice/Clinical Pharmacy Department, Faculty of Pharmacy, Egyptian Russian UniversitySchool of Pharmaceutical Sciences, Universiti Sains MalaysiaDivision of Population Medicine, Cardiff UniversityAbstract Introduction Atorvastatin is regarded as the most frequently prescribed statin worldwide for dyslipidemia. However, clinical response and risk of adverse effects to statin therapy are associated with genetic variations. Numerous research linked statins pharmacokinetics (PK) variations to genetic polymorphisms in cytochromes P450 (CYPs) metabolic enzymes. Objective This article reviews the association between CYP3A4/5 genetic variations and response to atorvastatin therapy globally, which includes atorvastatin PK, and the risk for adverse reactions, with a hint to the Egyptians. Methods Up to March 30, 2022, electronic medical databases like PubMed, Web of Science, MEDLINE, and Egyptian Knowledge Bank (EKB) were searched. All articles that highlighted the relationship between CYP3A4/5 genetic polymorphisms and atorvastatin efficacy/safety profile were included in this review. Results Initially, 492 articles were retrieved after an exhaustive search. There were 24 articles included according to the inclusion criteria. Findings of association studies of CYP3A4/5 genetic polymorphisms with response to atorvastatin varied among different ethnicities. CYP3A4*1B was associated with better therapeutic outcomes after atorvastatin therapy in Chileans and vice versa in Americans. Caucasians with myalgia while using atorvastatin were at significant risk of suffering severe muscle damage if they were carriers of CYP3A5*3/*3. As far as we can report for the Egyptian population, the impact of CYP3A4/5 genetic variations on the response to atorvastatin therapy was understudied. Conclusion More pharmacogenetic studies amongst diverse populations worldwide, like the Egyptian population, are necessary to detect further atorvastatin-gene interactions. Graphical Abstracthttps://doi.org/10.1186/s40001-023-01038-1Cytochromes P450CYP3A4CYP3A5PolymorphismAtorvastatinAdverse effect |
| spellingShingle | Mohammed G. Maslub Mahasen A. Radwan Nur Aizati Athirah Daud Abubakar Sha’aban Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population? European Journal of Medical Research Cytochromes P450 CYP3A4 CYP3A5 Polymorphism Atorvastatin Adverse effect |
| title | Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population? |
| title_full | Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population? |
| title_fullStr | Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population? |
| title_full_unstemmed | Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population? |
| title_short | Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population? |
| title_sort | association between cyp3a4 cyp3a5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide is there enough research on the egyptian population |
| topic | Cytochromes P450 CYP3A4 CYP3A5 Polymorphism Atorvastatin Adverse effect |
| url | https://doi.org/10.1186/s40001-023-01038-1 |
| work_keys_str_mv | AT mohammedgmaslub associationbetweencyp3a4cyp3a5geneticpolymorphismsandtreatmentoutcomesofatorvastatinworldwideisthereenoughresearchontheegyptianpopulation AT mahasenaradwan associationbetweencyp3a4cyp3a5geneticpolymorphismsandtreatmentoutcomesofatorvastatinworldwideisthereenoughresearchontheegyptianpopulation AT nuraizatiathirahdaud associationbetweencyp3a4cyp3a5geneticpolymorphismsandtreatmentoutcomesofatorvastatinworldwideisthereenoughresearchontheegyptianpopulation AT abubakarshaaban associationbetweencyp3a4cyp3a5geneticpolymorphismsandtreatmentoutcomesofatorvastatinworldwideisthereenoughresearchontheegyptianpopulation |